Gilead Sciences | GILD - Umsatzkosten





Umsatzkosten Veränderung Datum
AbbVie USD 4.22B 329M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
ALKERMES USD 73.25M 27.04M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amgen USD 1.6B 187M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Incyte USD 104.5M 16.68M 2026-03
J&J USD 8B 67M 2026-06
Merck USD 2.94B 380M 2026-03
Moderna USD 955M 503M 2026-03
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.67B 621M 2026-03
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
United Therapeutics USD 133.4M 341.3M 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03